NCT02218606View on ClinicalTrials.gov

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone acetate 1000 mg po daily

DRUG

Cabazitaxel 25 mg/m2 IV

DRUG

prednisone 5 mg po BID

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medical Center, New York

19107

Thomas Jefferson University Hospital, Philadelphia

23502

Virginia Oncology Associates, Norfolk

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Thomas Jefferson University

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02218606 - Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter